A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder

NSI-189 is a novel neurogenic compound independent of monoamine reuptake pathways. This trial evaluated oral NSI-189 as monotherapy in major depressive disorder. To improve signal detection, the sequential-parallel comparison design (SPCD) was chosen. Two hundred and twenty subjects were randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Papakostas, G. I., Johe, K., Hand, H., Drouillard, A., Russo, P., Kay, G., Kashambwa, R., Hoeppner, B., Flynn, M., Yeung, A., Martinson, M. A., Fava, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303010/
https://www.ncbi.nlm.nih.gov/pubmed/30626911
http://dx.doi.org/10.1038/s41380-018-0334-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303010/
https://www.ncbi.nlm.nih.gov/pubmed/30626911
http://dx.doi.org/10.1038/s41380-018-0334-8

Ejemplares similares